Form 4: Tarsus Pharmaceuticals COO Seshadri Neervannan Reports Stock Transactions

Chief Operating Officer of Tarsus Pharmaceuticals, Seshadri Neervannan, reports the acquisition of 21,264 shares of common stock and the vesting of several tranches of Restricted Stock Units (RSUs).

Summary

• Seshadri Neervannan, the Chief Operating Officer of Tarsus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 15, 2025, Neervannan acquired 21,264 shares of common stock through the settlement of vested Restricted Stock Units (RSUs).
• These RSUs were granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan on March 9, 2022, March 8, 2023, and March 7, 2024.
• The vesting schedule for these RSUs is 25% annually, contingent upon continuous service.
• Neervannan also acquired 1,234 shares under the Issuer's Employee Stock Purchase Plan on June 30, 2024.
• Following these transactions, Neervannan directly owns 87,265 shares of common stock.
• Neervannan also holds 5,097 RSUs granted on March 9, 2022, 16,296 RSUs granted on March 8, 2023, and 24,060 RSUs granted on March 7, 2024.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing. The sentiment is neutral, with a slight positive bias due to the executive increasing their stake in the company.

Positives

• The vesting of RSUs and subsequent acquisition of shares by a key executive could be seen as a positive sign of confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment.

Key Dates